Exemestane and Cyclophosphamide for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well exemestane and cyclophosphamide work in treating
patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and
human epidermal growth factor receptor (HER)2-negative stage IV breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health